RayKnowChina Research Map
Shortlist

Hangzhou

Zhejiang Provincial People's Hospital

浙江省人民医院

Listed for 27 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Zhejiang Provincial People's Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌4 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌4 papers led
  3. Hepatocellular carcinoma肝细胞癌119 papers led
  4. Stomach cancer胃癌38 papers led
  5. Lung cancer肺癌69 papers led1 open trial led
  6. Pancreatic cancer胰腺癌53 papers led3 open trials led
  7. Breast cancer乳腺癌74 papers led1 open trial led
  8. Glioma胶质瘤24 papers led1 open trial led
  9. Retinoblastoma视网膜母细胞瘤0 papers led
  10. Osteosarcoma骨肉瘤4 papers led
  11. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  12. Neuroblastoma神经母细胞瘤1 paper led
  13. Ewing sarcoma尤文肉瘤0 papers led
  14. Multiple myeloma多发性骨髓瘤10 papers led
  15. Lymphoma淋巴瘤15 papers led1 open trial led
  16. Myasthenia gravis重症肌无力2 papers led
  17. Coronary heart disease冠心病12 papers led
  18. Congenital heart disease先天性心脏病5 papers led
  19. Scoliosis脊柱侧弯3 papers led
  20. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
  21. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  22. Fabry disease法布雷病1 paper led
  23. Duchenne muscular dystrophy杜氏肌营养不良0 papers led
  24. Behçet disease白塞病0 papers led
  25. IgA nephropathyIgA 肾病4 papers led
  26. Primary biliary cholangitis原发性胆汁性胆管炎4 papers led
  27. Primary sclerosing cholangitis原发性硬化性胆管炎2 papers led

Not listed for: Hepatoblastoma, Chordoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Pompe disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 4 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 2220242025: 002025

8 hospitals in Hangzhou for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
    Phase
    N/A
    Started
    2023-06
    Posted
    Registry
    NCT05892354

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Guangxi Medical University; 13 listed hospitals as study sitesFuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Liuzhou, Nanchang, Nanning, Wuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersENT / head & neck surgery

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 4 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 3320242025: 002025

6 hospitals in Hangzhou for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesMolecular markers & genomicsImmunotherapyNeoadjuvant & combined treatment
Departments in papersRadiation oncology
Papers it led4
  1. Immune checkpoint inhibitors as the second-line treatment for advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis based on network meta-analysis.2024BMC cancerFree full text
  2. Lymph node ratio is a prognostic indicator for locally advanced esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy.2024Biomolecules & biomedicineFree full text
  3. Annexin A2 combined with TTK accelerates esophageal cancer progression via the Akt/mTOR signaling pathway.2024Cell death & diseaseFree full text
  4. Ubiquitin‑conjugating enzymes as potential biomarkers and therapeutic targets for digestive system cancers (Review).2023Oncology reportsFree full text
All its trials on ClinicalTrials.gov, any status2
  1. A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid TumorsStatus unknownNCT05602792Study sitePhase 1/Phase 2Start 2020-04
  2. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
More papers found outside PubMed (not counted)12
  1. Long-Term Outcomes of Dose Escalation in Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized Phase III Trial2025International Journal of Radiation Oncology*Biology*Physicsarticle
  2. Abstract CT213: Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C2024Cancer Researchconference-abstract
  3. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C.2024Journal of Clinical Oncologyconference-abstract
  4. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial, ALTER-G-001-cohort C.2024Journal of Clinical Oncologyconference-abstract
  5. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from multi-cohort, multi-center phase II trial ALTER-G-001-cohort A.2024Journal of Clinical Oncologyconference-abstract
  6. Effect of PLCE1-driven aerobic glycolysis through ENO1 modulation on immune evasion in esophageal squamous cell carcinoma (ESCC).2024Journal of Clinical Oncologyconference-abstract
  7. 103P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A2023Annals of Oncologyarticle
  8. 150P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C2023Annals of Oncologyarticle
  9. 1628P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001)2023Annals of Oncologyarticle
  10. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Results from a multi-cohort, multicenter phase II trial (ALTER-G-001).2023Journal of Clinical Oncologyconference-abstract
  11. P-104 Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001)2023Annals of Oncologyconference-abstract
  12. Epigenetically inhibiting CYP3A5 modulates the migration and invasion of esophageal squamous cell carcinoma via ZEB22022Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 119 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.8%.

Papers led
119
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 191920212022: 232320222023: 212120232024: 282820242025: 24242025

7 hospitals in Hangzhou for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrence & prognosisSurgery & liver transplantImaging, AI & early detection
Departments in papersSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineGastroenterology / hepatologyRadiology / nuclear medicine
Papers it led119
  1. Development and validation of machine learning-based model for predicting early recurrence for patients with HBV-associated hepatocellular carcinoma after curative hepatectomy.2026American journal of surgery
  2. Hepatic stellate cells shape the ECM-disorganized and immunosuppressive microenvironment via CCL11/CCR3 axis in lenvatinib-treated hepatocellular carcinoma.2026Cellular signalling
  3. Development and validation of a personalized web-based calculator of aggressive recurrence after surgery for early-stage hepatocellular carcinoma by machine learning.2026Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  4. A non-invasive decision tree predicting recurrence-free survival after liver transplantation for hepatocellular carcinoma.2026Hepatobiliary & pancreatic diseases international : HBPD INT
  5. Tumor-Targeted PLGA Nanospheres Enhance Therapeutic Effect of Lenvatinib in Hepatocellular Carcinoma via Photothermal and Photodynamic Therapy.2025ACS applied materials & interfaces
  6. Cancer Cell-Derived Exosomal miR-500a-3p Modulates Hepatic Stellate Cell Activation and the Immunosuppressive Microenvironment.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  7. Transcription factor FOXC2 regulates miR-145/ADAMTS5 axis to inhibit angiogenesis in hepatocellular carcinoma via circular RNA 0002898.2025BMC cancerFree full text
  8. Machine learning predicts post-transplant muscle loss in hepatocellular carcinoma patients without sarcopenia.2025BMC cancerFree full text
  9. Epigenetic-modification associated hnRNPA3 acts as a prognostic biomarker and promotes malignant progression of HCC.2025BMC cancerFree full text
  10. Developing a novel predictive model for identifying risk factors associated with being lost to follow-up among high-risk patients for recurrence following radical resection of hepatocellular carcinoma: the first report.2025BMC cancerFree full text
  11. Radiofrequency ablation combined with immunotherapy to treat hepatocellular carcinoma: a comprehensive review.2025BMC surgeryFree full text
  12. Noninvasive prediction of Glypican-3 expression in hepatocellular carcinoma using Habitat-based and peritumoral CT radiomics: a nomogram approach.2025Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  13. RSK2-mediated phosphorylation and degradation of UBE2O inhibits hepatocellular carcinoma growth and resistance to radiotherapy.2025Cancer letters
  14. YY1 induced USP13 transcriptional activation drives the malignant progression of hepatocellular carcinoma by deubiquitinating WWP1.2025Cellular & molecular biology lettersFree full text
  15. IGF2BP1/AIFM2 axis regulates ferroptosis and glycolysis to drive hepatocellular carcinoma progression.2025Cellular signalling
  16. Targeting Glycolytic Enzymes with 3-Bromopyruvic Acid to Enhance the Efficacy of Interventional Embolization in Hepatocellular Carcinoma.2025Current medical science
  17. Mesenchymal circulating tumor cells as prognostic markers in HCC Post-Transplantation: Sirolimus as a potential therapeutic Modulator.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  18. Outcomes and risk factors for liver transplantation using steatotic grafts for hepatocellular carcinoma: a multicenter study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  19. Dual-Mode Treatment of Hepatocellular Carcinoma Using RGD Cyclopeptide-Modified Liposomes Loaded with Ce6/DOX.2025International journal of nanomedicineFree full text
  20. Parkin modulates the hepatocellular carcinoma microenvironment by regulating PD-1/PD-L1 signalling.2025Journal of advanced researchFree full text
  21. Tumor-microenvironment responsive nanomodulator for near infrared photothermal immunotherapy of hepatocellular carcinoma.2025Journal of nanobiotechnologyFree full text
  22. Multi-omic analysis reveals a CAF-stemness-governed classification in HCC liver transplant recipients beyond the Milan criteria.2025Nature communicationsFree full text
  23. Perioperative and long-term outcomes of laparoscopic liver resection for combined hepatocellular carcinoma and cholangiocarcinoma versus intrahepatic cholangiocarcinoma: A propensity score matching analysis.2025PloS oneFree full text
  24. The value of prealbumin in predicting post hepatectomy liver failure for patients with hepatocellular carcinoma undergoing major hepatectomy.2025Scientific reportsFree full text
  25. Prognostic poteintial of polyamine metabolism-related genes in hepatocellular carcinoma.2025Scientific reportsFree full text
  26. Radiomics analysis based on dynamic contrast-enhanced MRI for predicting early recurrence after hepatectomy in hepatocellular carcinoma patients.2025Scientific reportsFree full text
  27. Unraveling the Causal Links Between Immune Traits and Hepatocellular Carcinoma: Insights From a Bi-Directional Mendelian Randomization Study.2025The Turkish journal of gastroenterology : the official journal of Turkish Society of GastroenterologyFree full text
  28. Prediction of posthepatectomy liver failure in patients with hepatocellular carcinoma through ultrasound elastography.2025World journal of gastroenterologyFree full text
  29. Peptide Transporter 1-Mediated Dipeptide Transport Promotes Hepatocellular Carcinoma Metastasis by Activating MAP4K4/G3BP2 Signaling Axis.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  30. Dual effects of targeting neuropilin-1 in lenvatinib-resistant hepatocellular carcinoma: inhibition of tumor growth and angiogenesis.2024American journal of physiology. Cell physiology
  31. Development and validation of prealbumin-bilirubin score (preALBI score) for predicting long-term survival after hepatectomy for hepatocellular carcinoma: A multicenter analysis versus ALBI score.2024American journal of surgery
  32. The Prognostic Value of Preoperative Serum Markers and Risk Classification in Patients with Hepatocellular Carcinoma.2024Annals of surgical oncology
  33. Survival benefit from adjuvant TACE combined with lenvatinib for patients with hepatocellular carcinoma and microvascular invasion after curative hepatectomy.2024Asian journal of surgery
  34. Establishment of a novel ferroptosis-correlative lncRNA signature and validation of ST3GAL4-AS1 for predicting overall survival of hepatocellular carcinoma.2024Asian journal of surgery
  35. Survival benefit of adjuvant TACE for patients with hepatocellular carcinoma and child-pugh B7 or B8 after hepatectomy.2024BMC cancerFree full text
  36. Chitinase-3 like-protein-1, a prognostic biomarker in patients with hepatocellular carcinoma and concomitant myosteatosis.2024BMC cancerFree full text
  37. Comparison of percutaneous microwave/radiofrequency ablation liver partition and portal vein embolization versus transarterial chemoembolization and portal vein embolization for planned hepatectomy with insufficient future liver remnant.2024BMC cancerFree full text
  38. Identification and validation of palmitoylation metabolism-related signature for liver hepatocellular carcinoma.2024Biochemical and biophysical research communications
  39. FAM188B promotes the growth, metastasis, and invasion of hepatocellular carcinoma by targeting the hnRNPA1/PKM2 axis.2024Biochimica et biophysica acta. Molecular cell research
  40. UCHL3 promotes hepatocellular carcinoma progression by stabilizing EEF1A1 through deubiquitination.2024Biology directFree full text
  41. OTUD5 promotes the growth of hepatocellular carcinoma by deubiquitinating and stabilizing SLC38A1.2024Biology directFree full text
  42. USP40 promotes hepatocellular carcinoma cell proliferation, migration and stemness by deubiquitinating and stabilizing Claudin1.2024Biology directFree full text
  43. Impact of immunosuppressants on tumor pulmonary metastasis: new insight into transplantation for hepatocellular carcinoma.2024Cancer biology & medicineFree full text
  44. Underlying mechanisms and management strategies for regorafenib-induced toxicity in hepatocellular carcinoma.2024Expert opinion on drug metabolism & toxicology
  45. Multicenter propensity score-matched analysis to compare perioperative morbidity after laparoscopic or robotic complex hepatectomy for solitary hepatocellular carcinoma.2024HPB : the official journal of the International Hepato Pancreato Biliary Association
  46. Mild photothermal activation of TRPV1 pathway for enhanced calcium ion overload therapy of hepatocellular carcinoma.2024International journal of biological macromolecules
  47. Unveiling the Role of Mechanical Microenvironment in Hepatocellular Carcinoma: Molecular Mechanisms and Implications for Therapeutic Strategies.2024International journal of biological sciencesFree full text
  48. Black Phosphorus Nanosheets-Loaded Single-Atom Gold Nanoenzymes for Enhanced Photodynamic Therapy of Hepatocellular Carcinoma.2024International journal of nanomedicineFree full text
  49. Letter to Editor: 'Identification of patients with favorable prognosis after resection in intermediate-stage hepatocellular carcinoma'.2024International journal of surgery (London, England)Free full text
  50. Myosteatosis and muscle loss impact liver transplant outcomes in male patients with hepatocellular carcinoma.2024Journal of cachexia, sarcopenia and muscleFree full text
  51. LYRM2 Promotes the Growth and Metastasis of Hepatocellular Carcinoma via Enhancing HIF-1α-Dependent Glucose Metabolic Reprogramming.2024Journal of cellular and molecular medicineFree full text
  52. Letter to the editor: 'A simple scoring system to predict early recurrence after surgical resection for hepatocellular carcinoma'.2024Liver international : official journal of the International Association for the Study of the Liver
  53. Transcription factor 7 like 2 promotes metastasis in hepatocellular carcinoma via NEDD9-mediated activation of AKT/mTOR signaling pathway.2024Molecular medicine (Cambridge, Mass.)Free full text
  54. Inhibiting the compensatory elevation of xCT collaborates with disulfiram/copper-induced GSH consumption for cascade ferroptosis and cuproptosis.2024Redox biologyFree full text
  55. The p-MYH9/USP22/HIF-1α axis promotes lenvatinib resistance and cancer stemness in hepatocellular carcinoma.2024Signal transduction and targeted therapyFree full text
  56. Letter to the editor: "Risk factors, patterns, and outcome predictors of late recurrence in patients with hepatocellular carcinoma after curative resection: A large cohort study with long-term follow-up results".2024Surgery
  57. Comprehensive analysis of cell death genes in hepatocellular carcinoma based on multi-omics data.2023Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  58. Comparison of diagnostic performance of AFP, DCP and two diagnostic models in hepatocellular carcinoma: a retrospective study.2023Annals of hepatology
  59. Pure laparoscopic resection of a large caudate-lobe mass guided by three-dimensional reconstruction and green fluorescence navigation.2023Asian journal of surgery
  60. Prognostic value of platelet distribution width to lymphocyte ratio in patients with hepatocellular carcinoma following hepatectomy.2023BMC cancerFree full text
  61. MEX3C as a potential target for hepatocellular carcinoma drug and immunity: combined therapy with Lenvatinib.2023BMC cancerFree full text
  62. UBE2K promotes the malignant progression of hepatocellular carcinoma by regulating c-Myc.2023Biochemical and biophysical research communications
  63. Polydopamine-Modified Zeolite Imidazole Framework Drug Delivery System for Photothermal Chemotherapy of Hepatocellular Carcinoma.2023Biomacromolecules
  64. Upregulation of MED7 was associated with progression in hepatocellular carcinoma.2023Cancer biomarkers : section A of Disease markersFree full text
  65. The prognosis of elderly patients with hepatocellular carcinoma after curative hepatectomy a multicenter competing risk analysis.2023Clinics and research in hepatology and gastroenterology
  66. Exosomal miR-374c-5p derived from mesenchymal stem cells suppresses epithelial-mesenchymal transition of hepatocellular carcinoma via the LIMK1-Wnt/β-catenin axis.2023Environmental toxicology
  67. Survival benefit of adjuvant transcatheter arterial chemoembolization for patients with hepatocellular carcinoma after anatomical hepatectomy.2023Expert review of gastroenterology & hepatology
  68. Metabolic rearrangements and intratumoral heterogeneity for immune response in hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  69. Transcatheter arterial chemoembolization after percutaneous microwave ablation and portal vein embolization for advanced hepatocellular carcinoma.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  70. Association of severity in the grading of microvascular invasion with long-term oncological prognosis after liver resection for early-stage hepatocellular carcinoma: a multicenter retrospective cohort study from a hepatitis B virus-endemic 2023International journal of surgery (London, England)Free full text
  71. Five machine learning-based radiomics models for preoperative prediction of histological grade in hepatocellular carcinoma.2023Journal of cancer research and clinical oncologyFree full text
  72. Rab11-FIP4 interacts with ARF5 to promote cancer stemness in hepatocellular carcinoma.2023Journal of physiology and biochemistry
  73. Hypoxia-induced UBE2K promotes the malignant progression of HCC.2023Pathology, research and practice
  74. LncRNA FRMD6-AS1 promotes hepatocellular carcinoma cell migration and stemness by regulating SENP1/HIF-1α axis.2023Pathology, research and practice
  75. A novel metabolism-related gene signature in patients with hepatocellular carcinoma.2023PeerJFree full text
  76. Short- and long-term outcomes of laparoscopic versus open liver resection for large hepatocellular carcinoma: a propensity score study.2023Surgery today
  77. Preoperative prediction of macrotrabecular-massive hepatocellular carcinoma through dynamic contrast-enhanced magnetic resonance imaging-based radiomics.2023World journal of gastroenterologyFree full text
  78. Editorial: non-viral hepatocellular carcinoma surveillance-an increasingly severe public health issue.2022Alimentary pharmacology & therapeutics
  79. Letter: sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma.2022Alimentary pharmacology & therapeutics
  80. Diagnostic accuracy of circulating microRNAs for hepatitis C virus-associated hepatocellular carcinoma: a systematic review and meta-analysis.2022BMC infectious diseasesFree full text
  81. Actinidia chinensis Planch Root extract suppresses the growth and metastasis of hypopharyngeal carcinoma by inhibiting E2F Transcription Factor 1-mediated MNX1 antisense RNA 1.2022BioengineeredFree full text
  82. Graphene quantum dots mediated magnetic chitosan drug delivery nanosystems for targeting synergistic photothermal-chemotherapy of hepatocellular carcinoma.2022Cancer biology & therapyFree full text
  83. High expression of PPM1G is associated with the progression and poor prognosis of hepatocellular carcinoma.2022Cancer biomarkers : section A of Disease markersFree full text
  84. Resistance of Lenvatinib in Hepatocellular Carcinoma.2022Current cancer drug targets
  85. Letter to editor: Does age effect on the short- and long-term outcomes of patients undergoing liver resection for hepatocellular carcinoma?2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  86. Impact of diabetes mellitus on the long-term prognosis of patients with hepatocellular carcinoma after hepatectomy.2022Expert review of gastroenterology & hepatology
  87. Low expression of moonlight gene ALAD is correlated with poor prognosis in hepatocellular carcinoma.2022Gene
  88. Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty live2022Hepatobiliary & pancreatic diseases international : HBPD INT
  89. LncRNA ALKBH3-AS1 enhances ALKBH3 mRNA stability to promote hepatocellular carcinoma cell proliferation and invasion.2022Journal of cellular and molecular medicineFree full text
  90. Antiviral therapy, HBsAg seroclearance and late recurrence of hepatitis B-related hepatocellular carcinoma.2022Journal of hepatology
  91. HBsAg seroclearance and reduction in late recurrence of HBV-related HCC: Causality or co-existence?2022Journal of hepatology
  92. Methodological considerations regarding a gene signature to predict microvascular invasion in hepatocellular carcinoma.2022Journal of hepatology
  93. Preoperative prediction of microvascular invasion: Is invasive biopsy of HCC necessary?2022Journal of hepatology
  94. The association of microvascular invasion with satellite nodule, tumor multiplicity, tumor encapsulation and resection margin of hepatocellular carcinoma.2022Journal of hepatology
  95. The updated BCLC staging system needs further refinement: A surgeon's perspective.2022Journal of hepatology
  96. The correlation of fibrinogen-like protein-1 expression with the progression and prognosis of hepatocellular carcinoma.2022Molecular biology reportsFree full text
  97. PHF21A expression as a biomarker of hepatocellular carcinoma progression and prognosis.2022Neoplasma
  98. Konjac glucomannan enhances 5-FU-induced cytotoxicity of hepatocellular carcinoma cells via TLR4/PERK/CHOP signaling to induce endoplasmic reticulum stress.2022Oncology researchFree full text
  99. Impact of marital status on overall survival in patients with early-stage hepatocellular carcinoma.2022Scientific reportsFree full text
  100. Neoadjuvant immunotherapy for resectable hepatocellular carcinoma.2022The lancet. Gastroenterology & hepatology
  101. An oncolytic adenovirus delivering TSLC1 inhibits Wnt signaling pathway and tumor growth in SMMC-7721 xenograft mice model.2021Acta biochimica et biophysica Sinica
  102. Long-term oncologic outcomes of liver resection for hepatocellular carcinoma in adolescents and young adults: A multicenter study from a hepatitis B virus-endemic area.2021American journal of surgery
  103. Impacts of the SOAT1 genetic variants and protein expression on HBV-related hepatocellular carcinoma.2021BMC cancerFree full text
  104. Identification of Multiple Hub Genes and Pathways in Hepatocellular Carcinoma: A Bioinformatics Analysis.2021BioMed research internationalFree full text
  105. HIF-1α-activated TM4SF1-AS1 promotes the proliferation, migration, and invasion of hepatocellular carcinoma cells by enhancing TM4SF1 expression.2021Biochemical and biophysical research communications
  106. An Autophagy-Related Gene-Based Prognostic Risk Signature for Hepatocellular Carcinoma: Construction and Validation.2021Computational and mathematical methods in medicineFree full text
  107. Postoperative morbidity adversely impacts long-term oncologic prognosis following hepatectomy for hepatocellular carcinoma: A multicenter observational study.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  108. Development and validation of an individualized prediction calculator of postoperative mortality within 6 months after surgical resection for hepatocellular carcinoma: an international multicenter study.2021Hepatology international
  109. UBE2O promotes hepatocellular carcinoma cell proliferation and invasion by regulating the AMPKα2/mTOR pathway.2021International journal of medical sciencesFree full text
  110. Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma.2021Journal of hematology & oncologyFree full text
  111. Comment on: Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinoma.2021Liver international : official journal of the International Association for the Study of the Liver
  112. ZMYND8 promotes the growth and metastasis of hepatocellular carcinoma by promoting HK2-mediated glycolysis.2021Pathology, research and practice
  113. Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis.2021Redox biologyFree full text
  114. High expression of YKT6 associated with progression and poor prognosis of hepatocellular carcinoma.2021Scandinavian journal of gastroenterology
  115. Biointerfacing Antagonizing T-Cell Inhibitory Nanoparticles Potentiate Hepatocellular Carcinoma Checkpoint Blockade Therapy.2021Small (Weinheim an der Bergstrasse, Germany)
  116. Nanotechnology for Hepatocellular Carcinoma: From Surveillance, Diagnosis to Management.2021Small (Weinheim an der Bergstrasse, Germany)
  117. The Clinical Significance of RMI2 in Hepatocellular Carcinoma.2021Technology in cancer research & treatmentFree full text
  118. Low Expression of KAT6B May Affect Prognosis in Hepatocellular Carcinoma.2021Technology in cancer research & treatmentFree full text
  119. Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study.2021World journal of gastroenterologyFree full text
All its trials on ClinicalTrials.gov, any status3
  1. A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)Active, not recruitingNCT05904886Study sitePhase 3Start 2023-09
  2. A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCCCompletedNCT04948697Study sitePhase 2Start 2021-08
  3. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Study sitePhase 3Start 2020-10

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 38 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.4%.

Papers led
38
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 9920212022: 4420222023: 5520232024: 111120242025: 992025

9 hospitals in Hangzhou for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06632262

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunotherapy & targeted drugsPeritoneal spread & advanced diseaseEarly detection & endoscopy
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyMedical oncologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led38
  1. Prediction model based on gut microbiota as a non-invasive tool for gastric cancer diagnosis.2025Applied microbiology and biotechnologyFree full text
  2. ASPN was higher expression in gastric cancer and associated with poor prognosis through promoting invasion and migration and inducing macrophage M2 polarization.2025BMC cancerFree full text
  3. Histone lactylation drives METTL3 upregulation-mediated RNA m6A modification of CCT2 to hinder CD8+ T cell survival in gastric cancer.2025Cellular and molecular life sciences : CMLSFree full text
  4. Integrated analysis of single-cell and bulk transcriptomes reveals the prognostic value of polyamine metabolism biomarkers and immune microenvironment features in gastric cancer.2025Frontiers in immunologyFree full text
  5. NRAV promoted the malignant progression of gastric cancer.2025Gene
  6. FGL1 facilitates rather than suppresses anticancer immunity against microsatellite instable gastric cancer.2025Genes and immunity
  7. PICK1 modulates the proliferation and migration of gastric cancer cells by regulating TLR4.2025Journal of Zhejiang University. Science. BFree full text
  8. The Causal Role of Gut Microbiota and Immune Cell Mediation in Gastroenteropancreatic Neuroendocrine Neoplasms: A Mendelian Randomization Study.2025Neuroendocrinology
  9. Explore the role of CBS in stomach adenocarcinoma based on the sulfur-containing amino acid metabolism network.2025Scientific reportsFree full text
  10. 18F-FDG PET/CT metabolism multi-parameter prediction of chemotherapy efficacy in locally progressive gastric cancer.2024Annals of nuclear medicineFree full text
  11. M6A methylation of FKFB3 reduced pyroptosis of gastric cancer by NLRP3.2024Anti-cancer drugs
  12. RARB associated with MSI, affects progression and prognosis of gastric cancer.2024BMC gastroenterologyFree full text
  13. A prognostic risk model based on lactate metabolism and transport-related lncRNAs for gastric adenocarcinoma.2024Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  14. WYC-209 inhibited GC malignant progression by down-regulating WNT4 through RARα.2024Cancer biology & therapyFree full text
  15. WYC-209 suppresses gastric cancer by down-regulating FGF18 via inactivating the STAT3 signaling pathway.2024European journal of pharmacology
  16. F2RL3 Regulates Epithelial-Mesenchymal Transition and Angiogenesis in Gastric Cancer through the Rap1/MAPK Signaling Pathway.2024Frontiers in bioscience (Landmark edition)
  17. Weifuchun suppresses the malignancy of gastric cancer cells by targeting KPNA2 through miR-26a-5p-mediated destabilization and the deactivation of the MAPK signaling pathway.2024Journal of ethnopharmacology
  18. Galectin-1 Promotes Gastric Carcinoma Progression and Cisplatin Resistance Through the NRP-1/c-JUN/Wee1 Pathway.2024Journal of gastric cancerFree full text
  19. KIAA1429 promotes gastric cancer progression by destabilizing RASD1 mRNA in an m6A-YTHDF2-dependent manner.2024Journal of translational medicineFree full text
  20. The efficacy and safety of per-nasal "GTS partner" assisted traction technique for gastric endoscopic submucosal dissection: a prospective single-center randomized clinical trial.2024Surgical endoscopyRCTFree full text
  21. Prevalence and spectrum of cancer predisposition germline mutations in young patients with the common late-onset cancers.2023Cancer medicineFree full text
  22. KCND2: A prognostic biomarker and regulator of immune function in gastric cancer.2023Cancer medicineFree full text
  23. Helicobacter pylori Infection as a Predictor of Treatment Outcomes of Gastric Cancer: A Systematic Review and Meta-Analysis.2023Digestive diseases (Basel, Switzerland)
  24. Competing endogenous RNA network characterization of lymph node metastases in Leuran gastric cancer subtypes.2023Journal of cancer research and clinical oncologyFree full text
  25. Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study.2023World journal of surgical oncologyFree full text
  26. Clinicopathological study of gastric schwannoma and review of related literature.2022BMC surgeryFree full text
  27. Prognostic role of iodine values for gastric cancer after neoadjuvant chemotherapy: a strong independent prognostic factor.2022Diagnostic and interventional radiology (Ankara, Turkey)Free full text
  28. Identification of three immune subtypes characterized by distinct tumor immune microenvironment and therapeutic response in stomach adenocarcinoma.2022Gene
  29. TLR4 rs4986790 polymorphism confers risk to Helicobacter pylori infection in Zhejiang, China and its enlightenment to nursing care.2022Journal of clinical laboratory analysisFree full text
  30. Research progress on gut microbiota in patients with gastric cancer, esophageal cancer, and small intestine cancer.2021Applied microbiology and biotechnology
  31. Circular RNA circCOL6A3_030 is involved in the metastasis of gastric cancer by encoding polypeptide.2021BioengineeredFree full text
  32. Long non-coding RNA AL139002.1 promotes gastric cancer development by sponging microRNA-490-3p to regulate Hepatitis A Virus Cellular Receptor 1 expression.2021BioengineeredFree full text
  33. The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review.2021Cancer control : journal of the Moffitt Cancer CenterFree full text
  34. Transcription Factor CTCFL Promotes Cell Proliferation, Migration, and Invasion in Gastric Cancer via Activating DPPA2.2021Computational and mathematical methods in medicineFree full text
  35. Protein interacting with C-kinase 1 is involved in epithelial-mesenchymal transformation and suppresses progress of gastric cancer.2021Medical oncology (Northwood, London, England)
  36. Evaluation of the efficiency and safety of combined chemotherapy and molecular-targeted therapy in the treatment of advanced gastric cancer: A protocol for systematic review and meta-analysis.2021MedicineFree full text
  37. RORβ suppresses the stemness of gastric cancer cells by downregulating the activity of the Wnt signaling pathway.2021Oncology reportsFree full text
  38. Immunotherapy of gastric cancer: Past, future perspective and challenges.2021Pathology, research and practice
Chinese-language papers (not in the count)2
  1. [Clinical application of complete laparoscopic gastrectomy with function preservation of cardia in gastric carcinoma].2022Zhonghua yi xue za zhi
  2. [Integrin α5 promotes the proliferation, invasion and adhesion of gastric cancer by regulating the FAK/Src/Rac1 signaling pathway].2021Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status8
  1. Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic CancerCompletedNCT06464965Lead sponsorPhase 1Start 2024-07
  2. A Phase 2 Clinical Study of ABSK061 and ABSK043RecruitingNCT06632262Study sitePhase 2Start 2024-11
  3. A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in ChinaCompletedNCT06585501Study siteStart 2024-08
  4. A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric CarcinomaTerminatedNCT04718402Study sitePhase 1Start 2021-03
  5. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China ExtensionCompletedNCT04882241Study sitePhase 3Start 2020-07
  6. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  7. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)CompletedNCT03675737Study sitePhase 3Start 2018-11
  8. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China ExtensionWithdrawnNCT04859582Study sitePhase 3Start 2018-11

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 69 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
69
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 7720212022: 141420222023: 151520232024: 141420242025: 18182025

11 hospitals in Hangzhou for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06534762

    Age 18 years to 65 years (registered criteria)

    Led by Zhejiang Provincial People's HospitalHangzhou

  2. Recruiting
    Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06890598

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesAnyang, Beijing, Changsha, Chengdu, Chongqing, Foshan, Guangzhou, Hangzhou, Harbin, Jinan, Luoyang, Nanning, Shanghai, Shantou, Shenzhen, Suzhou, Taizhou, Tianjin, Wuhan, Xi'an

  3. Recruiting
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06632262

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Jinan, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiation oncologyRadiology / nuclear medicineMedical oncologyPathology / laboratory medicine
Papers it led69
  1. A KAT7-lncPVT1 positive feedback loop promotes lung cancer carcinogenesis and therapy resistance via H3K14ac/HDGF/PI3K/AKT Axis.2026International journal of biological macromolecules
  2. Analysis of setup error and setup efficiency in SBRT for non-small cell lung cancer via a surface-guided radiation therapy system.2025BMC cancerFree full text
  3. Utilization of artificial intelligence-based pulmonary nodule target reconstruction software in clinical practice education for standardized training residents.2025BMC medical educationFree full text
  4. LINC01214 Promotes Non-Small Cell Lung Cancer Through the miR-497-3p/HSP90AB1 Axis.2025Canadian respiratory journalFree full text
  5. DNA methylation-regulated HLA-C expression modulates immune responses and metabolic alterations to influence prognosis in mesothelioma.2025Cancer immunology, immunotherapy : CIIFree full text
  6. COL5A2-mediated endoplasmic reticulum stress promotes macrophage M2 polarization in lung adenocarcinoma.2025Cell stress & chaperonesFree full text
  7. LZTS3 represses tumorigenesis and radioresistance via CK1δ and β-TrCP-mediated ubiquitination pathway in lung cancer.2025Cellular signalling
  8. Multi-center study on the application potential of Siaα-2,6Gal in early and differential diagnosis of lung cancer.2025Clinica chimica acta; international journal of clinical chemistry
  9. MCOLN1-Mediated Endoplasmic Reticulum Stress Induces Autophagy to Facilitate Lung Cancer Growth, Migration, and Invasion.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  10. Efficacy and safety of esketamine for smoking cessation among patients diagnosed with lung cancer and major depression disorder: A randomized, placebo-controlled clinical trial.2025Journal of affective disordersRCT
  11. USP28-mediated deubiquitination of FOXK1 activates the Hippo signaling pathway to regulate cell proliferation and radiosensitivity in lung cancer.2025Life sciences
  12. Immunotherapy in EGFR-mutant NSCLC after TKI resistance: role of mutation subtypes and progression patterns.2025Lung cancer (Amsterdam, Netherlands)
  13. Temozolomide and anlotinib as second-line therapy for non-small cell lung cancer patients with brain metastases: a retrospective cohort study.2025Neoplasma
  14. Comparative dosimetric evaluation of single-beam dual-arc versus dual-beam single-arc volumetric modulated arc therapy strategies in lung stereotactic body radiotherapy using Monaco.2025PeerJFree full text
  15. A retrospective study of automatic progressive optimization for lung cancer radiotherapy plans on the Halcyon and RayStation systems.2025PeerJFree full text
  16. Poricoic Acid A, an Active Ingredient Extracted From Poria cocos, Inhibits Lung Cancer Cell Growth by Suppressing MEK/ERK Signaling Pathway.2025Phytotherapy research : PTR
  17. Dosimetric comparison of Monte Carlo, Acuros XB, and anisotropic analytical algorithm for lung cancer plans on halcyon accelerators.2025PloS oneFree full text
  18. Comparative analysis of VMAT plans on Halcyon and infinity for lung cancer radiotherapy.2025PloS oneFree full text
  19. Combined utility of genomic breakpoints and frame is a reliable predictor of ALK transcript function.2025Scientific reportsFree full text
  20. Downregulated CDK10 promotes cancer progression and radioresistance in lung cancer through activating the JNK/c-Jun signaling pathway.2024BMB reportsFree full text
  21. Impact of immunosuppressants on tumor pulmonary metastasis: new insight into transplantation for hepatocellular carcinoma.2024Cancer biology & medicineFree full text
  22. COX6C expression driven by copy amplification of 8q22.2 regulates cell proliferation via mediation of mitosis by ROS-AMPK signaling in lung adenocarcinoma.2024Cell death & diseaseFree full text
  23. A clinical-radiological predictive model for solitary pulmonary nodules and the relationship between radiological features and pathological subtype.2024Clinical radiology
  24. Re: peritumoural MRI radiomics signature of brain metastases can predict epidermal growth factor receptor mutation status in lung adenocarcinoma.2024Clinical radiology
  25. NPM3 as an Unfavorable Prognostic Biomarker Involved in Oncogenic Pathways of Lung Adenocarcinoma via MYC Translational Activation.2024Combinatorial chemistry & high throughput screening
  26. microRNA-486-5p Regulates DNA Damage Inhibition and Cisplatin Resistance in Lung Adenocarcinoma by Targeting AURKB.2024Critical reviews in eukaryotic gene expression
  27. Sanguinarine Attenuates Lung Cancer Progression via Oxidative Stress-induced Cell Apoptosis.2024Current molecular pharmacology
  28. Hypoxia A Typical Target in Human Lung Cancer Therapy.2024Current protein & peptide science
  29. Diagnostic Potential of Serum Glycome Analysis in Lung Cancer: A Glycopattern Study.2024Journal of proteome research
  30. Pan-cancer landscape analysis of NOP58 and its oncogenic driving role in lung adenocarcinoma.2024Scientific reportsFree full text
  31. Multi-instance learning based lung nodule system for assessment of CT quality after small-field-of-view reconstruction.2024Scientific reportsFree full text
  32. A combination of radiomic features, clinic characteristics, and serum tumor biomarkers to predict the possibility of the micropapillary/solid component of lung adenocarcinoma.2024Therapeutic advances in respiratory diseaseFree full text
  33. Prognostic value of lymph node metrics in lung squamous cell carcinoma: an analysis of the SEER database.2024World journal of surgical oncologyFree full text
  34. Promotion of Lung Cancer Metastasis by SIRT2-Mediated Extracellular Protein Deacetylation.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  35. Diosbulbin C, a novel active ingredient in Dioscorea bulbifera L. extract, inhibits lung cancer cell proliferation by inducing G0/G1 phase cell cycle arrest.2023BMC complementary medicine and therapiesFree full text
  36. SIRP-alpha-IL-6 axis induces immunosuppressive macrophages in non-small-cell lung cancer.2023Biochemical and biophysical research communications
  37. The roles, molecular interactions, and therapeutic value of CDK16 in human cancers.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  38. Thirdhand Smoke May Promote Lung Adenocarcinoma Development through HN1.2023Computational and mathematical methods in medicineFree full text
  39. 68Ga-cyc-DX600 PET/CT in ACE2-targeted tumor imaging.2023European journal of nuclear medicine and molecular imagingFree full text
  40. Case Report: Life-threatening pancytopenia with tislelizumab followed by cerebral infarction in a patient with lung adenocarcinoma.2023Frontiers in immunologyFree full text
  41. Case report: Interstitial lung disease of XELOEX chemotherapy with cetuximab in advanced colon cancer induced.2023MedicineFree full text
  42. A real-world study of recombinant human endostatin combined with PD-1/PD-L1 blockade and chemotherapy for patients with advanced non-small cell lung cancer negative for actionable molecular biomarkers.2023MedicineFree full text
  43. Molecular characterization of genomic breakpoints of ALK rearrangements in non-small cell lung cancer.2023Molecular oncologyFree full text
  44. Novel insights into molecular patterns of ROS1 fusions in a large Chinese NSCLC cohort: a multicenter study.2023Molecular oncologyFree full text
  45. Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats.2023PeerJFree full text
  46. Predicting diagnosis and survival of bone metastasis in breast cancer using machine learning.2023Scientific reportsFree full text
  47. Circ_MACF1 targets miR-421 to upregulate FMO2 to suppress paclitaxel resistance and malignant cellular behaviors in lung adenocarcinoma.2023Thoracic cancerFree full text
  48. Lung cancer patient with Tropheryma whipplei and Nocardia co-infection.2023Ultrastructural pathology
  49. Development of Deep Learning-based Automatic Scan Range Setting Model for Lung Cancer Screening Low-dose CT Imaging.2022Academic radiology
  50. TECPR1 Induces Apoptosis in Non-Small Cell Lung Carcinoma via ATG5 Upregulation-Induced Autophagy Promotion.2022Annals of clinical and laboratory science
  51. The CT delta-radiomics based machine learning approach in evaluating multiple primary lung adenocarcinoma.2022BMC cancerFree full text
  52. Radiation recall pneumonitis triggered by an immune checkpoint inhibitor following re-irradiation in a lung cancer patient: a case report.2022BMC pulmonary medicineFree full text
  53. Knockdown of lncRNA PCAT6 suppresses the growth of non-small cell lung cancer cells by inhibiting macrophages M2 polarization via miR-326/KLF1 axis.2022BioengineeredFree full text
  54. Classification and Segmentation Algorithm in Benign and Malignant Pulmonary Nodules under Different CT Reconstruction.2022Computational and mathematical methods in medicineFree full text
  55. Novel immunotherapeutic drugs for the treatment of lung cancer.2022Current opinion in oncology
  56. Two Novel Nomograms Predicting the Risk and Prognosis of Pancreatic Cancer Patients With Lung Metastases: A Population-Based Study.2022Frontiers in public healthFree full text
  57. Afatinib treatment in a lung adenocarcinoma patient harboring a rare EGFR L747P mutation.2022Journal of cancer research and therapeutics
  58. Novel compound ZCJ14, a gefitinib analog, exhibited prominent anti-cancer effect among several cancer cell lines.2022Life sciences
  59. Risk and Incidence of Infection with Bevacizumab in Non-Small-Cell Lung Cancer Patients: A Meta-Analysis.2022Oncology research and treatment
  60. The prognosis of different distant metastases pattern in malignant tumors of the adrenal glands: A population-based retrospective study.2022PloS oneFree full text
  61. Neoadjuvant immunotherapy for resectable hepatocellular carcinoma.2022The lancet. Gastroenterology & hepatology
  62. Down-regulation of CLEC3B facilitates epithelial-mesenchymal transition, migration and invasion of lung adenocarcinoma cells.2022Tissue & cell
  63. Nitric oxide in occurrence, progress and therapy of lung Cancer: a systemic review and meta-analysis.2021BMC cancerFree full text
  64. Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer.2021Cell biochemistry and functionFree full text
  65. Surface-engineered smart nanocarrier-based inhalation formulations for targeted lung cancer chemotherapy: a review of current practices.2021Drug deliveryFree full text
  66. MiR-96-5p is an oncogene in lung adenocarcinoma and facilitates tumor progression through ARHGAP6 downregulation.2021Journal of applied genetics
  67. A comparative study of auto-contouring softwares in delineation of organs at risk in lung cancer and rectal cancer.2021Scientific reportsFree full text
  68. The prognosis and clinicopathological features of different distant metastases patterns in renal cell carcinoma: analysis based on the SEER database.2021Scientific reportsFree full text
  69. Establishment of a regression model of bone metabolism markers for the diagnosis of bone metastases in lung cancer.2021World journal of surgical oncologyFree full text
Chinese-language papers (not in the count)1
  1. [Seromucinous hamartoma in the lung: report of a case].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
All its trials on ClinicalTrials.gov, any status8
  1. Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical StudyRecruitingNCT06534762Lead sponsorPhase 2Start 2024-07
  2. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerRecruitingNCT06890598Study sitePhase 3Start 2025-03
  3. A Phase 2 Clinical Study of ABSK061 and ABSK043RecruitingNCT06632262Study sitePhase 2Start 2024-11
  4. A Study of PM8002 in Combination With Chemotherapy in Patients With SCLCActive, not recruitingNCT05879068Study sitePhase 2Start 2022-05
  5. Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung CancerCompletedNCT05014815Study sitePhase 2Start 2021-11
  6. Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.CompletedNCT05068427Study sitePhase 2Start 2021-11
  7. A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) PatientsStatus unknownNCT04237805Study sitePhase 1/Phase 2Start 2016-11
  8. Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable DiseaseStatus unknownNCT01690390Study sitePhase 2Start 2012-09

Run the PubMed searchClinicalTrials.gov

Cancer

Pancreatic cancer

胰腺癌

Led 53 of the 5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025: 0.9%.

Papers led
53
2021–2025
Trials led
9
any status, ClinicalTrials.gov
Open trials led
3
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 111120212022: 101020222023: 6620232024: 8820242025: 14142025

9 hospitals in Hangzhou for pancreatic cancer192 hospitals in China for pancreatic cancer

Open trials with this hospital 8

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07312422

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Provincial People's HospitalHangzhou

  2. Recruiting
    Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06534762

    Age 18 years to 65 years (registered criteria)

    Led by Zhejiang Provincial People's HospitalHangzhou

  3. Recruiting
    Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06722911

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Provincial People's HospitalHangzhou

  4. Recruiting
    A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07255404

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Kunming, Nanchang, Shanghai, Shenyang, Wuhan, Zhengzhou

  5. Recruiting
    A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
    Phase
    Phase 2/Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06361888

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Suzhou, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  6. Recruiting
    A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
    Phase
    Phase 2
    Started
    2023-05
    Posted
    Registry
    NCT05859750

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Jinan, Shanghai, Wuhan

  7. Recruiting
    A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
    Phase
    Phase 1
    Started
    2023-07
    Posted
    Registry
    NCT05911217

    Age 18 years to 79 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Shanghai, Wuhan, Xi'an, Zhengzhou

  8. Recruiting
    A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
    Phase
    Phase 2
    Started
    2023-10
    Posted
    Registry
    NCT06008288

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineMedical oncologyRadiology / nuclear medicine
Papers it led53
  1. Diagnostic performance of artificial intelligence based on contrast-enhanced computed tomography in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.2026Abdominal radiology (New York)
  2. 18F-FDG PET Radiomic Analysis to Predict Occult Liver Metastases of Pancreatic Ductal Adenocarcinoma.2026Academic radiology
  3. PIM1 protects pancreatic ductal cancer cells from glucose deprivation-induced oxidative stress via OXR1 phosphorylation.2026Biochimica et biophysica acta. Molecular basis of disease
  4. Extracellular Vesicle-Derived Adenosine as a Diagnostic Metabolic Biomarker for Pancreatic Ductal Adenocarcinoma.2026Cancer research and treatmentFree full text
  5. The acidic microenvironment promotes pancreatic cancer progression via the lncRNA-LOC100507424/E2F1/FOXM1 axis.2025BMC cancerFree full text
  6. A novel oncolytic poxvirus carrying CD47 nanomabs in the treatment of pancreatic cancer by reshaping the immune microenvironment.2025Cancer letters
  7. SCGB3A1-Epi and KLK10-Epi Crosstalk With Fibroblasts Promotes Liver Metastasis of Breast Cancer and Pancreatic Ductal Adenocarcinoma.2025Cancer medicineFree full text
  8. A clinically applicable machine learning model for personalized survival prediction in metastatic pancreatic neuroendocrine tumors.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  9. Oncogenic Role of PTPN14 in Pancreatic Cancer Through β-Catenin/NF-κB Pathway Activation.2025IUBMB life
  10. STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer.2025Journal of gastroenterology
  11. Small bowel obstruction in patients associated with immune checkpoint inhibitors combined with chemotherapy: Two case reports and a review.2025MedicineFree full text
  12. The Causal Role of Gut Microbiota and Immune Cell Mediation in Gastroenteropancreatic Neuroendocrine Neoplasms: A Mendelian Randomization Study.2025Neuroendocrinology
  13. PLA2G16 expression predicts prognosis and gemcitabine sensitivity in patients with pancreatic cancer.2025PeerJFree full text
  14. TSPAN15 sustains ITGB1 stability to block gemcitabine-induced ferroptosis in pancreatic ductal adenocarcinoma through the FAK/AKT/Mtor-gpx4 cascade.2025Redox biologyFree full text
  15. Predicting textbook outcome after pancreaticoduodenectomy for invasive intraductal papillary mucinous neoplasm: An international validation cohort study.2025Surgery
  16. β-hydroxybutyrate dehydrogenase promotes pancreatic cancer cell proliferation through regulation of the NAD+/NADH balance and mitochondrial acetylation.2025The Journal of biological chemistryFree full text
  17. Antioxidant capacity of the iron-sulfur cluster assembly protein IscU2 is mediated by aspartate metabolism to promote tumor survival.2025The Journal of biological chemistryFree full text
  18. Delayed gastric emptying risk stratification in patients with pancreatic ductal adenocarcinoma after pancreatoduodenectomy: An international validation cohort study.2025United European gastroenterology journalFree full text
  19. PAK1 inhibition increases TRIM21-induced PD-L1 degradation and enhances responses to anti-PD-1 therapy in pancreatic cancer.2024Biochimica et biophysica acta. Molecular basis of disease
  20. Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  21. WTAP/IGF2BP3-mediated GBE1 expression accelerates the proliferation and enhances stemness in pancreatic cancer cells via upregulating c-Myc.2024Cellular & molecular biology lettersFree full text
  22. Single-cell transcriptomics reveal the prognostic roles of epithelial and T cells and DNA methylation-based prognostic models in pancreatic cancer.2024Clinical epigeneticsFree full text
  23. Expression of GPX4 by oncolytic vaccinia virus can significantly enhance CD8+T cell function and its impact against pancreatic ductal adenocarcinoma.2024OncoimmunologyFree full text
  24. Interpretable multitemporal liver function indicator model for prediction and risk factor analysis of drug induced liver injury.2024Scientific reportsFree full text
  25. A smart tablet-phone-based high-performance pancreatic cancer cell biosensing system for drug screening.2024Talanta
  26. Quantitative assessment of the associations between DNA repair gene XRCC3 Thr241Met polymorphism and pancreatic cancer.2024World journal of surgical oncologyFree full text
  27. Causal effect between gut microbiota and pancreatic cancer: a two-sample Mendelian randomization study.2023BMC cancerFree full text
  28. Biological characteristics of pancreatic ductal adenocarcinoma: Initiation to malignancy, intracellular to extracellular.2023Cancer letters
  29. An Update on Gemcitabine-Based Chemosensitization Strategies in Pancreatic Ductal Adenocarcinoma.2023Frontiers in bioscience (Landmark edition)
  30. Roles of lncRNAs in pancreatic ductal adenocarcinoma: Diagnosis, treatment, and the development of drug resistance.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  31. UBE2K regulated by IGF2BP3 promotes cell proliferation and stemness in pancreatic ductal adenocarcinoma.2023International journal of oncologyFree full text
  32. Factors predicting recurrence after left‑sided pancreatectomy for pancreatic ductal adenocarcinoma.2023World journal of surgical oncologyFree full text
  33. Tumor-mutation burden as a marker for immunotherapy of pancreatic cancer: the case report and literature review.2022Anti-cancer drugsFree full text
  34. Conversion therapy, palliative chemotherapy and surgery, which of these is the best treatment for locally advanced and advanced pancreatic cancer?2022Anti-cancer drugsFree full text
  35. CDC25C is a prognostic biomarker and correlated with mitochondrial homeostasis in pancreatic adenocarcinoma.2022BioengineeredFree full text
  36. CT-based differentiation of solid pseudopapillary neoplasm and nonfunctional neuroendocrine tumor of pancreas.2022Diagnostic and interventional radiology (Ankara, Turkey)Free full text
  37. Innate immunity in pancreatic cancer: Lineage tracing and function.2022Frontiers in immunologyFree full text
  38. Two Novel Nomograms Predicting the Risk and Prognosis of Pancreatic Cancer Patients With Lung Metastases: A Population-Based Study.2022Frontiers in public healthFree full text
  39. Algorithm-based care after pancreatic resection.2022Lancet (London, England)
  40. Laparoscopic duodenum-preserving pancreatic head resection with real-time indocyanine green guidance of different dosage and timing: enhanced safety with visualized biliary duct and its long-term metabolic morbidity.2022Langenbeck's archives of surgeryFree full text
  41. Functions and clinical applications of exosomes in pancreatic cancer.2022Molecular biology reportsFree full text
  42. PARP inhibitors diminish DNA damage repair for the enhancement of tumor photodynamic therapy.2022Photodiagnosis and photodynamic therapy
  43. ASO Author Reflections: Innovative Techniques for Laparoscopic Duodenum-Preserving Pancreatic Head Resection.2021Annals of surgical oncology
  44. Laparoscopic radical antegrade modular pancreatosplenectomy: preliminary experience with 10 cases.2021BMC surgeryFree full text
  45. Downregulation of long non-coding RNA LINC00460 inhibits the proliferation, migration and invasion, and promotes apoptosis of pancreatic cancer cells via modulation of the miR-320b/ARF1 axis.2021BioengineeredFree full text
  46. Radiomic nomogram based on MRI to predict grade of branching type intraductal papillary mucinous neoplasms of the pancreas: a multicenter study.2021Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  47. DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism.2021Cell death & diseaseFree full text
  48. Nomogram Predicts Risk and Prognostic Factors for Bone Metastasis of Pancreatic Cancer: A Population-Based Analysis.2021Frontiers in endocrinologyFree full text
  49. A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.2021Frontiers in immunologyFree full text
  50. The new role of riluzole in the treatment of pancreatic cancer through the apoptosis and autophagy pathways.2021Journal of cellular biochemistry
  51. MicroRNAs as biomarkers and perspectives in the therapy of pancreatic cancer.2021Molecular and cellular biochemistry
  52. Comparison of clinical outcomes and quality of life between laparoscopic distal pancreatectomy with or without spleen preservation.2021Surgical endoscopy
  53. Adult pancreatoblastoma: a case report.2021The Journal of international medical researchFree full text
Chinese-language papers (not in the count)4
  1. [Clinical analysis of splenic circulation control technology applied in minimally invasive radical resection of pancreatic neck and body cancer].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  2. [The outcomes of robotic-assisted enucleation for tumors located in uncinate process of pancreas in 16 cases].2024Zhonghua wai ke za zhi [Chinese journal of surgery]
  3. [Innovation and development of surgical techniques for pancreatic tumors].2024Zhonghua wai ke za zhi [Chinese journal of surgery]
  4. [Clinical effect of minimally invasive duodenum preserving pancreatic head resection for benign and pre-malignant lesions of pancreatic head].2022Zhonghua wai ke za zhi [Chinese journal of surgery]
All its trials on ClinicalTrials.gov, any status16
  1. LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm StudyRecruitingNCT07312422Lead sponsorPhase 1/Phase 2Start 2025-09
  2. Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical StudyRecruitingNCT06534762Lead sponsorPhase 2Start 2024-07
  3. Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic CancerRecruitingNCT06722911Lead sponsorPhase 2Start 2024-11
  4. Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic CancerCompletedNCT06464965Lead sponsorPhase 1Start 2024-07
  5. Adjuvant Chemotherapy Plus Codonopsis Pilosula Nnannf /PlaceboStatus unknownNCT05613465Lead sponsorN/AStart 2022-10
  6. Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant ChemotherapyStatus unknownNCT04810910Lead sponsorPhase 1Start 2021-03
  7. Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic CancerTerminatedNCT03585062Lead sponsorPhase 2Start 2017-11
  8. Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic CancerCompletedNCT03645148Lead sponsorPhase 1Start 2017-10
  9. Different Stapler Cartridge For Pancreatic Stump Texture To Prevent Pancreatic FistulaCompletedNCT02790333Lead (inferred)N/AStart 2016-05
  10. A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic CancerRecruitingNCT07255404Study sitePhase 2Start 2025-12
  11. A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic CancerRecruitingNCT06361888Study sitePhase 2/Phase 3Start 2024-05
  12. A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic CancerRecruitingNCT05859750Study sitePhase 2Start 2023-05
  13. A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.RecruitingNCT06008288Study sitePhase 2Start 2023-10
  14. A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic CancerRecruitingNCT05911217Study sitePhase 1Start 2023-07
  15. A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic CancerCompletedNCT04228601Study sitePhase 1/Phase 2Start 2020-01
  16. Laparoscopic vs Open Pancreatectomy for Body and Tail Pancreatic CancerStatus unknownNCT03792932Study siteN/AStart 2019-02

Run the PubMed searchClinicalTrials.gov

Cancer

Breast cancer

乳腺癌

Led 74 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.4%.

Papers led
74
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 7720212022: 121220222023: 181820232024: 121220242025: 23232025

9 hospitals in Hangzhou for breast cancer219 hospitals in China for breast cancer

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06534762

    Age 18 years to 65 years (registered criteria)

    Led by Zhejiang Provincial People's HospitalHangzhou

  2. Recruiting
    A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06966700

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Changchun, Changsha, Hangzhou, Harbin, Hefei, Jinan, Nanjing, Nanning, Shanghai, Urumqi, Wuhan, Xi'an, Xiamen, Zhengzhou

  3. Recruiting
    The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06452706

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesHangzhou, Harbin, Shanghai, Urumqi, Wuhan, Xi'an

  4. Recruiting
    Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
    Phase
    Phase 3
    Started
    2023-10
    Posted
    Registry
    NCT05696626

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 57 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Kunming, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  5. Recruiting
    Comparison of the Safety and Aesthetic Outcomes of a Novel Endoscopic-Assisted Breast-Conserving Surgery (SRRSHzb-EABCS) With Those of Conventional Breast-Conserving Surgery
    Phase
    N/A
    Started
    2023-07
    Posted
    Registry
    NCT07920094

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sir Run Run Shaw Hospital; 10 listed hospitals as study sitesHangzhou, Jinhua, Ningbo, Taizhou, Wenzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicineRadiation oncologyMedical oncologySurgery (general/hepatobiliary/pancreatic)
Papers it led74
  1. UBE2K promotes breast cancer growth by ubiquitinating and degrading STUB1 to regulate the PKA/CREB1 signaling pathway, forming a feedback loop.2026Biochimica et biophysica acta. Molecular basis of disease
  2. Uncovering the symptom relationship among sleep quality, anxiety, and depression in Chinese patients with breast cancer: multidimensional data validation using PSQI versus actigraphy.2026Journal of cancer survivorship : research and practice
  3. Senescence-Inducing Therapy Sequential NIR-II Mild Photothermal/Senolytic Therapy of Triple Negative Breast Cancer.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  4. Novel ATR/PARP1 Dual Inhibitors Demonstrate Synergistic Antitumor Efficacy in Triple-Negative Breast Cancer Models.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  5. Clinical Experience in the Management of the Polyacrylamide Hydrogel (PAAG) Associated Complications Including Four Breast Cancer Cases: A Retrospective Study of 135 Cases.2025Aesthetic plastic surgery
  6. Luminol/PtCo@rGO and Au@CNTs-based electrochemiluminescence cytosensor for ultrasensitive detection of breast cancer CTCs.2025Analytica chimica acta
  7. Development and validation of an 18F-FDG PET/CT radiomic nomogram for predicting axillary lymph-node status after neoadjuvant chemotherapy for breast cancer: a multicenter study.2025Annals of nuclear medicineFree full text
  8. Trends in the global, national, and regional burden of breast cancer among adolescents and young adults from 1990 to 2021: Analyses of the 2021 global burden of disease study.2025Breast (Edinburgh, Scotland)Free full text
  9. Normal weight obesity, circulating biomarkers and risk of breast cancer: a prospective cohort study and meta-analysis.2025British journal of cancerFree full text
  10. Relation knowledge distillation 3D-ResNet-based deep learning for breast cancer molecular subtypes prediction on ultrasound videos: a multicenter study.2025British journal of cancerFree full text
  11. Interpretable Machine Learning for Predicting Neoadjuvant Chemotherapy Response in Breast Cancer Using the Baseline Clinical and Pathological Characteristics.2025Cancer medicineFree full text
  12. SCGB3A1-Epi and KLK10-Epi Crosstalk With Fibroblasts Promotes Liver Metastasis of Breast Cancer and Pancreatic Ductal Adenocarcinoma.2025Cancer medicineFree full text
  13. Breast Cancer in Working-Age Men: A Population-Based Investigation of Global, Regional, and National Disease Burdens Between 1990 and 2021.2025Clinical breast cancer
  14. Resveratrol contributes to NK cell-mediated breast cancer cytotoxicity by upregulating ULBP2 through miR-17-5p downmodulation and activation of MINK1/JNK/c-Jun signaling.2025Frontiers in immunologyFree full text
  15. Engineered macrophages in breast Cancer: bridging targeted therapy and advanced drug delivery.2025International immunopharmacology
  16. Integrative single-cell and bulk RNA sequencing of lactate metabolism identifies PDP-1 as a prognostic biomarker in breast cancer.2025International journal of biological macromolecules
  17. MR imaging of breast cancer: Interpretable radiomics analysis to assess treatment response and survival prognosis after neoadjuvant therapy.2025International journal of cancer
  18. Xihuang pill suppresses breast cancer malignancy by inhibiting TGF-β signaling and acquires chemotherapy benefits.2025Journal of ethnopharmacology
  19. Acetylation suppresses breast cancer progression by sustaining CLYBL stability.2025Journal of translational medicineFree full text
  20. Fibroblast Activation Protein (FAP)+ cancer-associated fibroblasts induce macrophage M2-like polarization via the Fibronectin 1-Integrin α5β1 axis in breast cancer.2025Oncogene
  21. Enhancing breast magnetic resonance imaging segmentation with a federated semi-supervised approach.2025Scientific reportsFree full text
  22. Implication of an exosome-based gene signature for estimating clinical outcomes of triple-negative breast cancer and assisting in individualized therapy.2025Scientific reportsFree full text
  23. Machine learning analysis of coagulation-related genes for breast cancer diagnosis and prognosis prediction.2025Scientific reportsFree full text
  24. The impact of axillary lymph node dissection on the prognosis of breast cancer patients undergoing up-front mastectomy with Sentinel lymph node micrometastases.2025Scientific reportsFree full text
  25. Tumor-colonizing Pseudoalteromonas elyakovii metabolically reprograms the tumor microenvironment and promotes breast ductal carcinoma.2025mBioFree full text
  26. 3D-Printed Breast Prosthesis that Smartly Senses and Targets Breast Cancer Relapse.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  27. Prediction of neoadjuvant chemotherapy pathological complete response for breast cancer based on radiomics nomogram of intratumoral and derived tissue.2024BMC medical imagingFree full text
  28. Research progress in tumor angiogenesis and drug resistance in breast cancer.2024Cancer biology & medicineFree full text
  29. Acidosis activates breast cancer ferroptosis through ZFAND5/SLC3A2 signaling axis and elicits M1 macrophage polarization.2024Cancer letters
  30. Real-World Data on Pathological Response and Survival Outcomes After Neoadjuvant Chemotherapy in HER2-Low Breast Cancer Patients.2024Clinical breast cancer
  31. Whole transcriptome sequencing indicated the Anti-tumor immunity of NLRP3 in breast cancer.2024Genomics
  32. CDK2-activated TRIM32 phosphorylation and nuclear translocation promotes radioresistance in triple-negative breast cancer.2024Journal of advanced researchFree full text
  33. Predicting pathological complete response to neoadjuvant chemotherapy in breast cancer patients: use of MRI radiomics data from three regions with multiple machine learning algorithms.2024Journal of cancer research and clinical oncologyFree full text
  34. The crosstalk between benign thyroid disease and breast cancer: A single center study.2024MedicineFree full text
  35. Methylation modification of non-histone proteins in breast cancer: An emerging targeted therapeutic strategy.2024Pharmacological research
  36. The role of adjuvant endocrine treatment in ER+, PR-, HER2- early breast cancer: a retrospective study of real-world data.2024Scientific reportsFree full text
  37. Platelet Membrane Coated Cu9S8-SNAP for Targeting NIR-II Mild Photothermal Enhanced Chemodynamic/Gas Therapy of Triple-Negative Breast Cancer.2024Small (Weinheim an der Bergstrasse, Germany)
  38. Estimated cardiorespiratory fitness in relation to overall, breast and prostate cancer incidence: the Norwegian HUNT study.2023Annals of epidemiology
  39. Multidimensional analysis to elucidate the possible mechanism of bone metastasis in breast cancer.2023BMC cancerFree full text
  40. Risk factors for the development of severe breast cancer-related lymphedema: a retrospective cohort study.2023BMC cancerFree full text
  41. Gut microbiome causal impacts on the prognosis of breast cancer: a Mendelian randomization study.2023BMC genomicsFree full text
  42. Chemotherapy-induced exosomal circBACH1 promotes breast cancer resistance and stemness via miR-217/G3BP2 signaling pathway.2023Breast cancer research : BCRFree full text
  43. Synthesis of poly (L-cysteine)/g-C3N4 modified glassy carbon electrodes for electrochemical detection of methotrexate as a medicine for treatment of breast cancer in pharmaceutical fluid samples.2023Chemosphere
  44. Hsa-miR-105-5p acts as an oncogene in triple-negative breast cancer.2023Chinese medical journalFree full text
  45. Assessment of the safety and efficacy of combination chemotherapy and PD-1/PD-L1 inhibitor treatment of breast cancer: A meta-analysis.2023Chinese medical journalFree full text
  46. Establishing a Predictive Model to Predict Survival of de Novo Metastatic HER2-Low Breast Cancer: A National Cancer Database Analysis.2023Discovery medicine
  47. Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer.2023Frontiers in immunologyFree full text
  48. Integrated analysis of FKBP1A/SLC3A2 axis in everolimus inducing ferroptosis of breast cancer and anti-proliferation of T lymphocyte.2023International journal of medical sciencesFree full text
  49. Correlation between the setting of gating window width and setup accuracy in left breast cancer radiotherapy based on deep inspiration breath hold.2023Journal of applied clinical medical physicsFree full text
  50. Integrative landscape analysis of prognostic model biomarkers and immunogenomics of disulfidptosis-related genes in breast cancer based on LASSO and WGCNA analyses.2023Journal of cancer research and clinical oncologyFree full text
  51. NIR diagnostic imaging of triple-negative breast cancer and its lymph node metastasis for high-efficiency hypoxia-activated multimodal therapy.2023Journal of nanobiotechnologyFree full text
  52. OTUD1 chemosensitizes triple-negative breast cancer to doxorubicin by modulating P16 expression.2023Pathology, research and practice
  53. Predicting diagnosis and survival of bone metastasis in breast cancer using machine learning.2023Scientific reportsFree full text
  54. FKBP5 associated CD8 T cell infiltration is a novel prognostic biomarker in luminal B breast cancer.2023The Journal of international medical researchFree full text
  55. Breast cancer organoids and their applications for precision cancer immunotherapy.2023World journal of surgical oncologyFree full text
  56. Engineered Red Blood Cell Membrane-Coating Salidroside/Indocyanine Green Nanovesicles for High-Efficiency Hypoxic Targeting Phototherapy of Triple-Negative Breast Cancer.2022Advanced healthcare materials
  57. Two-dimensional speckle tracking echocardiography help identify breast cancer therapeutics-related cardiac dysfunction.2022BMC cardiovascular disordersFree full text
  58. Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis.2022BMJ openFree full text
  59. Thyrotropin suppression therapy using levothyroxine does not negatively affect breast cancer prognosis.2022Cancer treatment and research communications
  60. Overview of PROTACs Targeting the Estrogen Receptor: Achievements for Biological and Drug Discovery.2022Current medicinal chemistry
  61. Identification of Ferroptosis-Related Prognostic Signature and Subtypes Related to the Immune Microenvironment for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.2022Frontiers in immunologyFree full text
  62. miR-10b-5p-mediated upregulation of PIEZO1 predicts poor prognosis and links to purine metabolism in breast cancer.2022Genomics
  63. Autophagy-related prognostic signature for survival prediction of triple negative breast cancer.2022PeerJFree full text
  64. Metastasis patterns and prognosis of octogenarians with metastatic breast cancer: A large-cohort retrospective study.2022PloS oneFree full text
  65. Effect of postoperative radiotherapy in women with localized pure mucinous breast cancer after lumpectomy: a population-based study.2022Radiation oncology (London, England)Free full text
  66. Breast metastasis of signet ring cell carcinoma from the colon: a case report.2022World journal of surgical oncologyFree full text
  67. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective stu2022World journal of surgical oncologyFree full text
  68. Integrative genomic analysis of N6-methyladenosine-single nucleotide polymorphisms (m6A-SNPs) associated with breast cancer.2021BioengineeredFree full text
  69. Lnc-DC promotes estrogen independent growth and tamoxifen resistance in breast cancer.2021Cell death & diseaseFree full text
  70. Naringenin Regulates FKBP4/NR3C1/NRF2 Axis in Autophagy and Proliferation of Breast Cancer and Differentiation and Maturation of Dendritic Cell.2021Frontiers in immunologyFree full text
  71. Role of immune regulatory cells in breast cancer: Foe or friend?2021International immunopharmacology
  72. Heparin-binding growth factor (HDGF) drives radioresistance in breast cancer by activating the STAT3 signaling pathway.2021Journal of translational medicineFree full text
  73. Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy.2021The Journal of international medical researchFree full text
  74. Identification of differentially methylated genes as diagnostic and prognostic biomarkers of breast cancer.2021World journal of surgical oncologyFree full text
Chinese-language papers (not in the count)2
  1. Estrogen upregulates DNA2 expression through the PI3K-AKT pathway in endometrial carcinoma.2023Journal of Zhejiang University. Science. BFree full text
  2. [Solid Tumors With Cold Agglutinins:Report of Two Cases and Literature Review].2023Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
All its trials on ClinicalTrials.gov, any status16
  1. Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical StudyRecruitingNCT06534762Lead sponsorPhase 2Start 2024-07
  2. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RecruitingNCT06966700Study sitePhase 3Start 2025-06
  3. The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast CancerRecruitingNCT06452706Study sitePhase 2Start 2024-11
  4. Comparison of the Safety and Aesthetic Outcomes of a Novel Endoscopic-Assisted Breast-Conserving Surgery (SRRSHzb-EABCS) With Those of Conventional Breast-Conserving SurgeryRecruitingNCT07920094Study siteN/AStart 2023-07
  5. Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationRecruitingNCT05696626Study sitePhase 3Start 2023-10
  6. A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)Active, not recruitingNCT06680921Study sitePhase 3Start 2024-11
  7. A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast CancerActive, not recruitingNCT05346224Study sitePhase 3Start 2022-04
  8. A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)Active, not recruitingNCT05296798Study sitePhase 3Start 2022-07
  9. A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerActive, not recruitingNCT05514054Study sitePhase 3Start 2022-10
  10. A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast CancerStatus unknownNCT05433480Study sitePhase 3Start 2022-05
  11. A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)TerminatedNCT04740918Study sitePhase 3Start 2021-06
  12. Breast Mesh Used in Two-staged Breast ReconstructionStatus unknownNCT04967976Study siteN/AStart 2021-08
  13. A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid TumorsStatus unknownNCT05602792Study sitePhase 1/Phase 2Start 2020-04
  14. Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)Active, not recruitingNCT03725059Study sitePhase 3Start 2018-12
  15. Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young WomenStatus unknownNCT02914158Study sitePhase 3Start 2016-03
  16. Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer PatientsStatus unknownNCT02062489Study sitePhase 3Start 2014-05

Run the PubMed searchClinicalTrials.gov

Cancer

Glioma

胶质瘤

Led 24 of the 7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025: 0.3%.

Papers led
24
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 5520222023: 2220232024: 5520242025: 772025

9 hospitals in Hangzhou for glioma187 hospitals in China for glioma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence
    Phase
    Not given
    Started
    2025-06
    Posted
    Registry
    NCT06939400

    Age 18 years to Not stated (registered criteria)

    Led by Zhejiang Provincial People's HospitalHangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurosurgeryPathology / laboratory medicineRadiology / nuclear medicineMedical oncology

Over half of these papers are lab or animal studies.

Papers it led24
  1. Metalloporphyrin organic framework oxygen-generators enable tumour-targeted photodynamic therapy and metabolic reprogramming for enhanced glioblastoma treatment.2026Journal of colloid and interface science
  2. Biomimetic platinum-based nanoplatform for photoacoustic imaging-guided multimodal glioblastoma therapy.2026Journal of colloid and interface science
  3. Integration of Single-Cell and Bulk RNA-seq Data to Identify the Cancer-Associated Fibroblast Subtypes and Risk Model in Glioma.2025Biochemical genetics
  4. Novel Insights Into Small Open Reading Frame-Encoded Micropeptides in Glioblastoma.2025Cell biology international
  5. Mechanistic Insights into the Anti-Glioma Effects of Exosome-Like Nanoparticles Derived from Garcinia Mangostana L.: A Metabolomics, Network Pharmacology, and Experimental Study.2025International journal of nanomedicineFree full text
  6. ApoE-Corona oncolytic adenovirus nanoparticles enable blood-brain barrier penetration for glioblastoma immunotherapy.2025Journal of controlled release : official journal of the Controlled Release Society
  7. Exosomal circ_0001583 Drives Glioblastoma Cell Advancement Through the miR-647/CKAP2L Pathway.2025Molecular neurobiologyFree full text
  8. Three Decades of Photodynamic Therapy for Glioblastoma: A Comprehensive Scientometric Analysis.2025Photodiagnosis and photodynamic therapy
  9. Glioma stem cells: drivers of tumor progression and recurrence.2025Stem cell research & therapyFree full text
  10. β-Mangostin targets and suppresses glioma via STING activation and tumor-associated microglia polarization.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  11. Multi-omics technologies and molecular biomarkers in brain tumor-related epilepsy.2024CNS neuroscience & therapeuticsFree full text
  12. Inhibition of circular JUN prevents the proliferation and invasion of glioblastoma via miR-3064-IGFBP5 axis.2024Journal of cellular and molecular medicineFree full text
  13. The Implication of Photodynamic Therapy Applied to the Level of Tumor Resection on Postoperative Cerebral Edema and Intracranial Pressure Changes in Gliomas.2024Lasers in surgery and medicine
  14. Turning attention to tumor-host interface and focus on the peritumoral heterogeneity of glioblastoma.2024Nature communicationsFree full text
  15. EGFR-Induced and c-Src-Mediated CD47 Phosphorylation Inhibits TRIM21-Dependent Polyubiquitylation and Degradation of CD47 to Promote Tumor Immune Evasion.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  16. The Heterogeneity of Tumour-Associated Macrophages Contributes to the Recurrence and Outcomes of Glioblastoma Patients.2023Journal of molecular neuroscience : MN
  17. NIR-II absorptive dithienopyrrole-thiadiazolobenzotriazole conjugated polymer for photoacoustic imaging-guided glioblastoma multiforme photothermal therapy.2022Acta biomaterialia
  18. Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers.2022Drug deliveryFree full text
  19. IGFBPs were associated with stemness, inflammation, extracellular matrix remodeling and poor prognosis of low-grade glioma.2022Frontiers in endocrinologyFree full text
  20. Inhibition of hypoxia-inducible factor 1 by acriflavine renders glioblastoma sensitive for photodynamic therapy.2022Journal of photochemistry and photobiology. B, Biology
  21. TRIM7 modulates NCOA4-mediated ferritinophagy and ferroptosis in glioblastoma cells.2022Redox biologyFree full text
  22. Role of circulating tumor cell detection in differentiating tumor recurrence from treatment necrosis of brain gliomas.2021Bioscience trends
  23. Platelet-Tumor Cell Hybrid Membrane-Camouflaged Nanoparticles for Enhancing Therapy Efficacy in Glioma.2021International journal of nanomedicineFree full text
  24. The Nomogram of MRI-based Radiomics with Complementary Visual Features by Machine Learning Improves Stratification of Glioblastoma Patients: A Multicenter Study.2021Journal of magnetic resonance imaging : JMRI
All its trials on ClinicalTrials.gov, any status1
  1. Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow FluorescenceNot yet recruitingNCT06939400Lead sponsorStart 2025-06

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led no English-language PubMed papers on retinoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Hangzhou for retinoblastoma176 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. miR-140-5p suppresses retinoblastoma cell proliferation, migration, and invasion by targeting CEMIP and CADM3.2018Cellular and molecular biology (Noisy-le-Grand, France)

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 4 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 1120242025: 112025

20 hospitals in Hangzhou for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

12 hospitals in Hangzhou for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

8 hospitals in Hangzhou for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

6 hospitals in Hangzhou for Ewing sarcoma134 hospitals in China for Ewing sarcoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2025-05
    Posted
    Registry
    NCT06926283

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Changsha, Hangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Clinicopathologic and molecular characteristics of malignant gastrointestinal neuroectodermal tumors].2017Zhonghua bing li xue za zhi = Chinese journal of pathology
All its trials on ClinicalTrials.gov, any status1
  1. A Study of DXC008 in Patients With Prostate Cancer and Other Solid TumorsRecruitingNCT06926283Study sitePhase 1Start 2025-05

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 10 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.6%.

Papers led
10
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 0020232024: 2220242025: 332025

9 hospitals in Hangzhou for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Posted
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskBispecific & antibody drugsRelapse & resistance
Departments in papersPathology / laboratory medicine
Papers it led10
  1. Reduced ALDH1A1 expression in multiple myeloma cells increases resistance to daratumumab via downregulation of retinoic acid.2025Cellular and molecular life sciences : CMLSFree full text
  2. Performance and comparison of FLCCheck: a novel serum free light chain assay for the Auxiliary Diagnosis of Multiple Myeloma.2025European journal of medical researchFree full text
  3. Safety assessment of proteasome inhibitors real world adverse event analysis from the FAERS database.2025Scientific reportsFree full text
  4. Regarding the prognostic role of vitamin D deficiency in a Japanese multiple myeloma study.2024Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  5. Immunoglobulin Replacement Therapy for Hypogammaglobulinemia in Multiple Myeloma Should Not Be Ignored.2024Turkish journal of haematology : official journal of Turkish Society of HaematologyFree full text
  6. Defects and countermeasures in laboratory diagnosis of rare IgE multiple myeloma.2022Clinica chimica acta; international journal of clinical chemistry
  7. Role of Tfh17 cells in patients with multiple myeloma.2022Hematology (Amsterdam, Netherlands)
  8. A patient with hypercalcemia and hyperparathyroidism due to adenoma mimicking multiple myeloma.2022International journal of laboratory hematology
  9. Secondary Immunodeficiency and Hypogammaglobulinemia with IgG Levels of <5 g/L in Patients with Multiple Myeloma: A Retrospective Study Between 2012 and 2020 at a University Hospital in China.2021Medical science monitor : international medical journal of experimental and clinical researchFree full text
  10. Bone marrow stromal cells derived exosomal miR-10a and miR-16 may be involved in progression of patients with multiple myeloma by regulating EPHA8 or IGF1R/CCND1.2021MedicineFree full text
All its trials on ClinicalTrials.gov, any status2
  1. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  2. BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT05376345Study sitePhase 1Start 2022-09

Run the PubMed searchClinicalTrials.gov

Blood disorders

Lymphoma

淋巴瘤

Led 15 of the 3,830 English-language PubMed papers on lymphoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
15
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 5520222023: 1120232024: 4420242025: 332025

8 hospitals in Hangzhou for lymphoma199 hospitals in China for lymphoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06534762

    Age 18 years to 65 years (registered criteria)

    Led by Zhejiang Provincial People's HospitalHangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicineRadiology / nuclear medicine
Papers it led15
  1. Tumor Pro-Senescence Strategy to Enhance Mild Photothermal Therapy of Diffuse Large B-Cell Lymphoma.2025ACS applied materials & interfaces
  2. Bi-targeting of thioredoxin 1 and telomerase by thiotert promotes cell death of myelodysplastic syndromes and lymphoma.2025Biology directFree full text
  3. Causal association between endocrine diseases and lymphoid malignancies explored through two-sample Mendelian randomization analysis.2025Scientific reportsFree full text
  4. C-MYC-activated lncRNA SNHG20 accelerates the proliferation of diffuse large B cell lymphoma via USP14-mediated deubiquitination of β-catenin.2024Biology directFree full text
  5. Ferroptosis mechanisms and its novel potential therapeutic targets for DLBCL.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  6. TNFAIP3 Overexpression Inhibits Diffuse Large B-Cell Lymphoma Progression by Promoting Autophagy through TLR4/MyD88/NF-κB Signaling Pathway.2024Discovery medicine
  7. Importance of Rare Gene Alterations in the Prognosis of B-Cell Acute Lymphoblastic Leukemia.2024Turkish journal of haematology : official journal of Turkish Society of HaematologyFree full text
  8. A patient with the highly suspected B cell lymphoma accompanied by the erythrocytes cold agglutination: Case report.2023MedicineFree full text
  9. Use of Ultrasound to Observe Mycosis Fungoides: A Case Report and Review of Literature.2022Current medical imaging
  10. Primary pulmonary mucosa-associated lymphoid tissue lymphoma with radiological presentation of middle lobe syndrome diagnosed by bronchoscopy: a case report.2022Hong Kong medical journal = Xianggang yi xue za zhi
  11. Caution the difference between the atypical lymphocyte with circulating Hodgkin lymphoma cells.2022International journal of laboratory hematology
  12. Pericardial involvement in a common B-cell acute lymphoblastic leukemia patient.2022International journal of laboratory hematology
  13. New-onset Systemic Lupus Erythematosus in a Woman with Previous Lymphoma during Late Pregnancy: a case report and literature review.2022Iranian journal of immunology : IJI
  14. Remodeling of the tumor microenvironment using an engineered oncolytic vaccinia virus improves PD-L1 inhibition outcomes.2021Bioscience reportsFree full text
  15. Beclin1‑armed oncolytic Vaccinia virus enhances the therapeutic efficacy of R‑CHOP against lymphoma in vitro and in vivo.2021Oncology reportsFree full text
All its trials on ClinicalTrials.gov, any status1
  1. Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical StudyRecruitingNCT06534762Lead sponsorPhase 2Start 2024-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 2 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

6 hospitals in Hangzhou for myasthenia gravis89 hospitals in China for myasthenia gravis

No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesAntibodies & diagnosis
Departments in papersRheumatology & immunologyNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Coronary heart disease

冠心病

Led 12 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.2%.

Papers led
12
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 3320232024: 3320242025: 442025

11 hospitals in Hangzhou for coronary heart disease231 hospitals in China for coronary heart disease

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07521007

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an

  2. Recruiting
    Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
    Phase
    Phase 4
    Started
    2025-11
    Posted
    Registry
    NCT07110415

    Age 40 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Dalian, Daqing, Guangzhou, Guiyang, Hangzhou, Harbin, Huzhou, Jinan, Lanzhou, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Xi'an, Yantai, Yinchuan, Zhangjiakou, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicineNephrology
Papers it led12
  1. The relationship between Non-HDL/HDL ratio and in-stent restenosis in patients with coronary artery atherosclerosis after percutaneous coronary intervention.2025BMC cardiovascular disordersFree full text
  2. Underlining the Molecular Mechanism of Nonalcoholic Fatty Liver Disease and Coronary Artery Disease in Lipid Metabolism by Combining Multiple Sets of Data Sets.2025IUBMB lifeFree full text
  3. Association of 24-Hour blood pressure average real variability with poor prognosis in critically ill patients with coronary artery disease.2025Scientific reportsFree full text
  4. Serum Angptl2 and CyPA Levels in Acute Myocardial Infarction and In-Stent Restenosis After Percutaneous Coronary Intervention: A Single-Center Retrospective Case-Control Study.2025Vascular health and risk managementFree full text
  5. Coronary artery calcium scoring assessment in ultra-low-dose chest computed tomography.2024Clinical imaging
  6. Shared Genetic Links Between Nonalcoholic Fatty Liver Disease and Coronary Artery Disease.2024Global heartFree full text
  7. Spontaneous multivessel coronary artery spasm: a case report.2024The Journal of invasive cardiology
  8. Lower Baseline LDL Cholesterol Affects All-cause Mortality in Patients with First Percutaneous Coronary Intervention.2023Biomedical and environmental sciences : BES
  9. Relationship between uric acid to albumin ratio and in-stent restenosis in patients with coronary artery disease undergoing drug-eluting stenting.2023Coronary artery diseaseFree full text
  10. Coronary computed tomography angiography imaging features combined with computed tomography-fractional flow reserve, pericoronary fat attenuation index, and radiomics for the prediction of myocardial ischemia.2023Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
  11. Coronary artery calcification in patients with advanced chronic kidney disease.2022BMC cardiovascular disordersFree full text
  12. Predicting Chronic Myocardial Ischemia Using CCTA-Based Radiomics Machine Learning Nomogram.2022Journal of nuclear cardiology : official publication of the American Society of Nuclear CardiologyRCT
All its trials on ClinicalTrials.gov, any status3
  1. Evaluation of Novel Risk Factors and Clinical Outcomes of Acute Myocardial InfarctionStatus unknownNCT02641184Lead sponsorStart 2015-12
  2. A Phase 2b Clinical Trial of YN001 in Adults With Coronary AtherosclerosisRecruitingNCT07521007Study sitePhase 2Start 2026-07
  3. Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac DysfunctionRecruitingNCT07110415Study sitePhase 4Start 2025-11

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital heart disease

先天性心脏病

Led 5 of the 2,604 English-language PubMed papers on congenital heart disease with an author in mainland China, 2021–2025: 0.2%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 4420242025: 112025

9 hospitals in Hangzhou for congenital heart disease207 hospitals in China for congenital heart disease

No open trial on congenital heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Scoliosis

脊柱侧弯

Led 3 of the 925 English-language PubMed papers on scoliosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 1120242025: 002025

6 hospitals in Hangzhou for scoliosis107 hospitals in China for scoliosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Protocol for a Randomized Controlled Trial of a Clinician-Supervised Home-School-Hospital-Linked Digital Health Platform-Supported Conservative Management Pathway for AIS
    Phase
    N/A
    Started
    2025-03
    Posted
    Registry
    NCT06314594

    Age 12 years to 16 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

10 hospitals in Hangzhou for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

10 hospitals in Hangzhou for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led 1 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 1.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

7 hospitals in Hangzhou for Fabry disease80 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Status and frontiers of Fabre disease.2025Orphanet journal of rare diseasesFree full text
Earlier papers (2016–2020)1
  1. Coexistence of Fabry disease with IgM nephropathy: A case report.2019Medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led no English-language PubMed papers on Duchenne muscular dystrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

7 hospitals in Hangzhou for Duchenne muscular dystrophy111 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Population-Wide Duchenne Muscular Dystrophy Carrier Detection by CK and Molecular Testing.2020BioMed research international

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

7 hospitals in Hangzhou for Behçet disease139 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet DiseaseTerminatedNCT04609397Study sitePhase 2Start 2020-11

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 4 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.5%.

Papers led
4
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 1120242025: 112025

10 hospitals in Hangzhou for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Papers it led4
  1. Global glomerulosclerosis proportions predict nephropathy progression in IgA nephropathy: a multicenter retrospective analysis with propensity score matching.2025Renal failureFree full text
  2. A patient report scale research to access the symptom burden in patients with IgA nephropathy.2024Scientific reportsFree full text
  3. Oral Methylprednisolone and Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy.2022JAMA
  4. Mesangial Cell-Derived Exosomal miR-4455 Induces Podocyte Injury in IgA Nephropathy by Targeting ULK2.2022Oxidative medicine and cellular longevityFree full text
Earlier papers (2016–2020)2
  1. iTRAQ-based comparative proteomics analysis reveals specific urinary biomarkers for various kidney diseases.2020Biomarkers in medicine
  2. How many podocyte autophagosomes are there in immunoglobulin A nephropathy and idiopathic membranous nephropathy?2016International urology and nephrology
All its trials on ClinicalTrials.gov, any status7
  1. MYTP01 for Immune-Mediated DiseasesNot yet recruitingNCT07901764Lead sponsorN/AStart 2026-12
  2. A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune DiseasesNot yet recruitingNCT06774664Study sitePhase 1/Phase 2Start 2025-01
  3. A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of ProgressionActive, not recruitingNCT05797610Study sitePhase 3Start 2023-08
  4. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  5. TESTING -ON Post-Trial ObservatioNal Cohort StudyCompletedNCT05434325Study siteStart 2022-12
  6. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09
  7. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)CompletedNCT01560052Study siteN/AStart 2012-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 4 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 1.3%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 3320242025: 002025

7 hospitals in Hangzhou for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunologySurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 2 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 2.0%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

6 hospitals in Hangzhou for primary sclerosing cholangitis89 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other linked evidence

Getting in touch

Name card to show staff or a driver

浙江省人民医院

Zhejiang Provincial People's Hospital

杭州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Zhejiang Provincial People's Hospital (Affiliated People's Hospital); Zhejiang Provincial People's Hospital (Affiliated People's Hospital; Zhejiang Provincial People's Hospital(Affiliated People's Hospital); Zhejiang Provincial People's Hospital Chun'an Branch; Zhejiang Provincial People's hospital; Zhejiang Provincial People's Hospital Bijie Hospital; Affiliated Zhejiang Provincial People's Hospital; Zhejiang Provincial People' s Hospital

Suggest a correctionDownload the data